{"name":"IntraBio Inc","slug":"intrabio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Aqneursa first approved","drug":"Aqneursa","drugSlug":"levacetylleucine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-12-01","label":"Aqneursa PHASE3 readout","drug":"Aqneursa","drugSlug":"levacetylleucine","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Aqneursa","genericName":"LEVACETYLLEUCINE","slug":"levacetylleucine","indication":"Niemann-Pick disease type C (NPC)","status":"marketed"},{"name":"N-Acetyl-L-Leucine","genericName":"N-Acetyl-L-Leucine","slug":"n-acetyl-l-leucine","indication":"Cerebellar ataxia","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"IB1001","genericName":"IB1001","slug":"ib1001","indication":"Multiple myeloma (in development)","status":"phase_3"}]}],"pipeline":[{"name":"Aqneursa","genericName":"LEVACETYLLEUCINE","slug":"levacetylleucine","phase":"marketed","mechanism":"Aqneursa works by modifying the activity of a specific enzyme involved in the breakdown of fatty substances in the body.","indications":["Niemann-Pick disease type C (NPC)"],"catalyst":""},{"name":"IB1001","genericName":"IB1001","slug":"ib1001","phase":"phase_3","mechanism":"IB1001 is an intrabone injection therapy designed to deliver therapeutic agents directly into the bone marrow microenvironment.","indications":["Multiple myeloma (in development)"],"catalyst":""},{"name":"N-Acetyl-L-Leucine","genericName":"N-Acetyl-L-Leucine","slug":"n-acetyl-l-leucine","phase":"phase_3","mechanism":"N-Acetyl-L-Leucine enhances mitochondrial energy metabolism and reduces neuroinflammation to improve vestibular and cerebellar function.","indications":["Cerebellar ataxia","Vertigo and balance disorders","Spinocerebellar ataxia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQQW9EUGkwOEtDblVwalp1WjFubDdfbTBwZ3E2T1RhSG4xRHpHdHRSUW9sNXMzYXFZSHp1UVZZcUFBRmVqYkdnQjJzVG53bzRTLUJfeUlISFFUbV9DZk45dUVPaXlROUZKTjF3NEJOZmJZQU0xZWhYVHRqZDNUNF9adXcwMERjTnRC?oc=5","date":"2026-01-22","type":"regulatory","source":"The Pharma Letter","summary":"IntraBio wins EC approval of Aqneursa - The Pharma Letter","headline":"IntraBio wins EC approval of Aqneursa","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOUGRvdWotU2l1cHhvUGgycER1Y0ZQT0kxWFBoOHhlekY4ai1oV2NVVThIbVZ4ekdjaU16cWlianV2SGp3dkpLcE5IYUhsUzJJdlBEQUszRjlJZUY3UWZrSUwyVjI0SmhBRDZsd09zVDNzbHRDOVNCb3lEQ2c4OE1xaXlXYWlBcXF2blRpaTJVNGVPbkNBdFRybnRWeUJvLVRLYXktWWhxdkt0RGlmeWJUN3drTEhFekh4TmJHczNlWUFFUGxUMDQw?oc=5","date":"2026-01-21","type":"regulatory","source":"Fierce Pharma","summary":"IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win - Fierce Pharma","headline":"IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPcXNkb19EcXJJVG93Wi10UTlSR0o3WGQ5UnJ6RVd5UXlaU3ROMzZWdFdPdlZaLVNCVnFNdXEyajVhT04tLUphLU52MXNPT0pnakhCbk5ZY1BXdV9SZDd1ZlNGdkdNZnluT2wzeUxUNW5YWGNLNExQdGEyM3F5VnF3N21xc1UyVmV5c3RkRDI4TDFxOGlvYnJQZWVWODFnb0JubEZLY0VobGJlWE15ZUZVbHlkMC1WM1otWlA0ODladVBfdXRXLWw1QUJKNlJ2MXpjTXFsdnlLVHJLR2lySkF0VFQxbmt2VW1hMDJHZVlsTk85NkFhMUtj?oc=5","date":"2026-01-21","type":"regulatory","source":"Business Wire","summary":"IntraBio Receives European Commission Approval of AQNEURSA® for the Treatment of Niemann-Pick Type C Disease - Business Wire","headline":"IntraBio Receives European Commission Approval of AQNEURSA® for the Treatment of Niemann-Pick Type C Disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9Zem9ZcElGOTBlcjBEOUI3ZzBxaHIyb1BmdW5ZTFhRUmc2cGMyOVp6Zm04aVcxRGpzZ0ZZWmxUSjJVcG5ubXZLRm9ETXRQZzdzT0hB?oc=5","date":"2026-01-21","type":"regulatory","source":"FirstWord Pharma","summary":"IntraBio moves to add second rare disease to Aqneursa's label - FirstWord Pharma","headline":"IntraBio moves to add second rare disease to Aqneursa's label","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQbUplT2xNNlY4M0wxM3pYak92V3hqTmhaZV9vaHV1VkZfNzlWQ2RpTWFIcm9qT2Z0M0pscXgxMDhULW4zajhJVHZCbERTc1B4aXVjWXRKUy1qb3NCTC1rZmJjRm5rZUN1U1EzNXhuZWpuV2wxelBkYXlpNVR3c2I0VVI0TmlheFBPRVhscUN1T3p3QU5ES1NTMkN3NVljTEtGeVMw?oc=5","date":"2025-10-15","type":"patent","source":"IAM Patent","summary":"Pharma start-up IntraBio and CEO Mallory Factor patently mean business - IAM Patent","headline":"Pharma start-up IntraBio and CEO Mallory Factor patently mean business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPbExmcm9FTXpsZW83WENfRENuU05telZWeGxlelNyOGlDb21fLVRaZndkajlRcldpVlZ2Zy1UX3IxT2tEa2hoMHV5a1lnVVRwXzR0UW9kZW1LNUMyYzRQdlpiYmxIdGZQRktIVV96SVBCY3FNYm1zekgycVBBYlNKWEltTkdjRnNPNVZKcXdxMmJLelRYTlRhQw?oc=5","date":"2025-05-12","type":"pipeline","source":"FinTech Magazine","summary":"EY Unveils Finance Service Built on SAP Cloud Technology - FinTech Magazine","headline":"EY Unveils Finance Service Built on SAP Cloud Technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMThoNWVoQk83RzdPZUdqYlQxNkhwV0RJem5lTlJFTUJGNmd6U1diYzMzYkRtUU9PY1ZObjNrakFIaU9MTG5SdWdrQTZiMXA2LU1ENDczM2RQZm9iajAwN0o5UGowNE81SjNRZFJOeWxudlZORVpiSTRmRjZIWWd1MHhhRUotc2c2NTlVY2ktYWhoQk9TbkxKUHh2SW9KZmZndWpVb2hrMmFiUQ?oc=5","date":"2025-04-04","type":"pipeline","source":"KEYE","summary":"Austin's IntraBio accelerates hope for rare neurological disease treatment - KEYE","headline":"Austin's IntraBio accelerates hope for rare neurological disease treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNbXA2aTNzZzVfa2ItcHFUYUtid2xvQ21qUEFSM1MtYzdYeUEzeWRNUW82WUdqcUFDWXlNUzZNVm5XcUo0RjlabUZKWXh4ckhBQUE0aThsOURXekRtdnBid19waERsM3RJOTJfNzF2X1ZkajBTaGlqWjRHR1hqcWlZQTRuQnlCRlA4SDJIdGRQNUFMX2Y2Q3R5V1dR?oc=5","date":"2024-10-30","type":"pipeline","source":"openPR.com","summary":"Current and Future Analysis of Tay-Sachs Disease Treatment - openPR.com","headline":"Current and Future Analysis of Tay-Sachs Disease Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOaHFRRHh0dU9QZzB1dDNCRTJiVkY5WTNQUTlrWEtabE9teDR0Y000aXFwbHYzMFBCMmJpUEtPMUdtUU85UlJKM3pSOHphQjBxWlQ0dU9TNVZXYmtJbUZJZE1vV3d2d1FSaXdqd1RpdFU3bTlnNUo1WnZ4OWotRXI1eHNkWG9hTHRKZ19hQ05wWW5jcGtlZEQ5TUVGUHEzdUU4LXpXbnJtRUhVQmNaNEt4dFlNOGFnNWZWbUEtNGtfTQ?oc=5","date":"2024-09-30","type":"regulatory","source":"Fierce Pharma","summary":"After landmark rare disease approval, IntraBio ready to 'hit the ground running' with Aqneursa launch - Fierce Pharma","headline":"After landmark rare disease approval, IntraBio ready to 'hit the ground running' with Aqneursa launch","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQNUJaVDQ0QnFhdVBhTV8yeklZZGlkbGhOd0FocUFmbnRiV3FzRTVidDdDYWlDVmpRaW5yYW5UblF4R1JfN3lVUFoxTTBjQXBCWWxHMndGcnNOVXJnOFJLVGxERzlRRnZsaW9hdnVmSWlNZkpBMWN3ZExhOE91VEsybDhwS0xQYVZDSXF1eF8yUWZ2d3JlT2RZbVpnZjk1ZmFoejJEWG5DQnpKS0tkdFlGa3Atcjh4U2xOU28zTGo1NA?oc=5","date":"2024-09-25","type":"pipeline","source":"Fierce Pharma","summary":"IntraBio muscles in on Zevra's turf after companies' back-to-back lysosomal storage disorder nods - Fierce Pharma","headline":"IntraBio muscles in on Zevra's turf after companies' back-to-back lysosomal storage disorder nods","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPZC1fX25IRzR1V3NOaHFqc0E4bWhmZXY2V2tsdi1TalFicmNvNWt6VzdnSWdfYzhENUtlWFkzbHA2Q0l5OURhNi0xSDg3aUplakVmZzZpenEtSHNnYk91WHhlSlIwLXh5bG1wUkpGM2RNSXhKV29Pa0xVazNycmhHX25Oa3pxZy1Yc1ZiQVIzUmp4NnBrRjdRSlJHUGh4NFVkV0JESXJLN1dXcWk4TUJiUUtTZkllQzZHeFpobWlkaUw?oc=5","date":"2024-09-24","type":"regulatory","source":"Reuters","summary":"US FDA approves IntraBio's drug for rare genetic disease - Reuters","headline":"US FDA approves IntraBio's drug for rare genetic disease","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2023-09-19","type":"regulatory","source":"PR Newswire","summary":"Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the Market - Azafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, IntraBio Inc, Mandos He","headline":"Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the Market - Azafaro","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}